Adams Revenue Grows 11% As Mucinex Sales Shift Toward Line Extensions
This article was originally published in The Tan Sheet
Executive Summary
Adams Respiratory Therapeutics' net sales grew 11 percent to $84 million in its latest quarter as sales of single-ingredient Mucinex were cannibalized by newer extensions in the product line
You may also be interested in...
Max Strength Mucinex Sales Could Reach $70M In Debut Season – Adams
Adams Respiratory Therapeutics projects sales of its forthcoming Maximum Strength Mucinex products will eventually make up 60 percent of total Mucinex sales, the firm said April 4
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.